METHOD FOR PREDICTING RISK OF DEATH IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH COVID-19 Russian patent published in 2022 - IPC G01N33/53 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely endocrinology, intensive care, and can be used in predicting the risk of death in patients with type 2 diabetes mellitus (DM2) in combination with COVID-19. To do this, in a patient with type 2 diabetes with COVID-19, the levels of urea, creatinine, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), C-reactive protein (CRP), international normalized ratio (INR), D-dimer, lactate dehydrogenase (LDH), leukocytes, erythrocyte sedimentation rate (ESR) are determined in the blood. With a combination of factors such as urea levels over 10.15 mmol/L, creatinine levels over 105.4 mmol/L, ALAT above 20.8 U/L, ASAT above 36.7 U/L, CRP above 98.2 mg/L, leukocytes over 10.7×109/L, ESR above 33.6 mm/h, INR above 1.02, D-dimer above 295.15 u/L, LDH above 516.09 U/L, lethal the outcome in patients with type 2 diabetes from COVID-19.

EFFECT: method provides prediction of the risk of death in patients with type 2 diabetes mellitus in combination with COVID-19 by determining certain significant diagnostic criteria.

1 cl, 2 tbl, 3 ex